文献速递类风湿关节炎脊柱关节炎系统性红斑狼疮

2007至2021年美国新诊断自身免疫性风湿病患者疼痛管理方式的年度趋势:一项基于行政索赔数据的研究

Annual trends in pain management modalities in patients with newly diagnosed autoimmune rheumatic diseases in the USA from 2007 to 2021: an administrative claims-based study.
PubMed 文献 · Lancet Rheumatol · 2024-06-27

该研究基于美国Merative Marketscan研究数据库2007至2021年数据,纳入141 962例新诊断的强直性脊柱炎、银屑病关节炎、类风湿关节炎、干燥综合征、系统性硬化症或系统性红斑狼疮患者,分析诊断后一年内疼痛管理方式年度趋势。结果显示阿片类药物使用在2014年前每年增加4%(aOR 1.04),2014年后每年减少15%(aOR 0.85);非阿片类疼痛管理方式使用增加或稳定,而阿片类和NSAIDs使用下降。

要点

  • 2014年后阿片类药物使用每年减少15%(aOR 0.85),NSAIDs使用每年减少5%(aOR 0.95)。
  • 2014年前物理治疗使用每年增加5%(aOR 1.05),2014年后每年略降1%(aOR 0.99)。
  • 抗惊厥药使用在2014年前每年增加7%(aOR 1.07),2014年后无显著变化(aOR 1.00)。

核心结论

  • 自2014年以来,非阿片类疼痛管理方式的使用增加或稳定,而阿片类和NSAIDs使用下降。
  • 未来研究需要评估这些变化的效果及其对生活质量、残疾和功能等结局的影响。

研究设计与样本

  • 基于美国Merative Marketscan研究数据库的行政索赔数据研究,纳入2007至2021年新诊断的强直性脊柱炎、银屑病关节炎、类风湿关节炎、干燥综合征、系统性硬化症或系统性红斑狼疮患者。
  • 共纳入141 962例患者:强直性脊柱炎10 927例,银屑病关节炎21 438例,类风湿关节炎71 393例,干燥综合征16 718例,系统性红斑狼疮18 018例,系统性硬化症3468例;女性107 475例(75.7%),男性34 487例(24.3%)。
  • 采用逻辑回归估计日历年与结局的关联,校正年龄、性别和地区。

主要发现

  • 阿片类药物使用发生率在2014年前每年增加4%(aOR 1.04 [95% CI 1.03-1.04]),2014年后每年减少15%(aOR 0.85 [95% CI 0.84-0.86])。
  • 物理治疗使用发生率在2014年前每年增加5%(aOR 1.05 [95% CI 1.04-1.06]),2014年后每年略降1%(aOR 0.99 [95% CI 0.98-1.00])。
  • 抗惊厥药使用发生率在2014年前每年增加7%(aOR 1.07 [95% CI 1.07-1.08]),2014年后无显著变化(aOR 1.00 [95% CI 0.99-1.00])。
  • NSAIDs使用发生率在2014年前每年增加2%(aOR 1.02 [95% CI 1.02-1.03]),2014年后每年减少5%(aOR 0.95 [95% CI 0.95-0.96])。
  • 除2014年前NSAIDs使用(交互作用P=0.02)和2014年后局部镇痛药使用(交互作用P=0.0100)外,趋势无性别差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 未来研究需要评估这些变化的效果及其对生活质量、残疾和功能等结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Autoimmune rheumatic diseases have distinct pathogenic mechanisms and are causes of disability and increased mortality worldwide. In this study, we aimed to examine annual trends in pain management modalities among patients with autoimmune rheumatic diseases. METHODS: We identified newly diagnosed patients with ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, Sjögren's syndrome, systemic sclerosis, or systemic lupus erythematosus (SLE) in the Merative Marketscan Research Databases from 2007 to 2021. The database includes deidentified inpatient and outpatient health encounters with employment-sponsored health insurance claims in the USA. We found minimal occurrences of multiple overlapping conditions and included only the initial recorded diagnosis for each patient. We determined the annual incidence of patients treated with opioids, anticonvulsants, antidepressants, skeletal muscle relaxants, non-steroidal anti-inflammatory drugs (NSAIDs), topical analgesics, and physical therapy in the year following diagnosis. Logistic regression was used to estimate the association between calendar year and outcomes, adjusted for age, sex, and region. FINDINGS: We included 141 962 patients: 10 927 with ankylosing spondylitis, 21 438 with psoriatic arthritis, 71 393 with rheumatoid arthritis, 16 718 with Sjögren's syndrome, 18 018 with SLE, and 3468 with systemic sclerosis. 107 475 (75·7%) were women and 34 487 (24·3%) were men. Overall, the incidence of opioid use increased annually until 2014 by 4% (adjusted odds ratio [aOR] 1·04 [95% CI 1·03-1·04]) and decreased annually by 15% after 2014 (0·85 [0·84-0·86]). The incidence of physical therapy use increased annually by 5% until 2014 (aOR 1·05 [95% CI 1·04-1·06]), with a slight decrease annually by 1% after 2014 (0·99 [0·98-1·00]). The incidence of anticonvulsant use increased annually by 7% until 2014 (aOR 1·07 [95% CI 1·07-1·08]) and did not significantly change after 2014 (1·00 [0·99-1·00]). Before 2014, the incidence of NSAIDs use increased by 2% annually (aOR 1·02 [95% CI 1·02-1·03]); however, after 2014, the incidence decreased annually by 5% (0·95 [0·95-0·96]). These trends did not differ by sex except for NSAID use before 2014 (pinteraction=0·02) and topical analgesic use after 2014 (pinteraction=0·0100). INTERPRETATION: Since 2014, the use of non-opioid pain management modalities has increased or stabilised, whereas opioid and NSAID use has declined. Future studies are needed to evaluate the effectiveness of these changes, and the effects they have had on outcomes such as quality of life, disability, and function. FUNDING: National Institute of Arthritis and Musculoskeletal and Skin Diseases.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Falasinnu T, Lu D, Baker MC, et al. Annual trends in pain management modalities in patients with newly diagnosed autoimmune rheumatic diseases in the USA from 2007 to 2021: an administrative claims-based study. Lancet Rheumatol. 2024. PMID: 38945137. doi:10.1016/S2665-9913(24)00120-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。